X4 Pharmaceuticals, Inc — Director's Dealing 2019

Jun 19, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: X4 Pharmaceuticals, Inc (XFOR)
CIK: 0001501697
Period of Report: 2019-06-17

Reporting Person: Ragan Paula (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-06-17	Common Stock	A	55928	$0.00	Acquired	237294	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-06-17	Stock Option (right to buy)	$14.75	A	83893	Acquired	2029-06-17	Common Stock (83893)	Direct

Footnotes

F1: Grant of restricted stock units to the Reporting Person under the Issuer's 2017 Equity Incentive Plan, with each restricted stock unit representing the contingent right to receive one share of common stock on the applicable vesting date. No amount was paid upon grant of the units. The restricted stock units vest in four equal annual installments on May 31, 2020, May 31, 2021, May 31, 2022 and May 31, 2023, subject to the Reporting Person continuing to provide services through each such date.

F2: Of the shares of common stock reported, 55,928 shares represent unvested restricted stock units.

F3: 25% of the shares subject to the option shall vest on June 17, 2020, with the remainder vesting in equal installments of 2.0833% of the shares subject to the option on the last day of each successive month thereafter for a period of 36 months, subject to the Reporting Person continuing to provide services through each such date.